Rocket Pharmaceuticals Statistics
Total Valuation
RCKT has a market cap or net worth of $415.43 million. The enterprise value is $169.14 million.
Important Dates
The next estimated earnings date is Monday, November 3, 2025, after market close.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RCKT has 107.90 million shares outstanding. The number of shares has increased by 13.53% in one year.
| Current Share Class | 107.90M |
| Shares Outstanding | 107.90M |
| Shares Change (YoY) | +13.53% |
| Shares Change (QoQ) | +0.84% |
| Owned by Insiders (%) | 2.76% |
| Owned by Institutions (%) | 66.71% |
| Float | 78.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.17 |
| P/TBV Ratio | 1.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.39, with a Debt / Equity ratio of 0.07.
| Current Ratio | 6.39 |
| Quick Ratio | 6.26 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -139.85 |
Financial Efficiency
Return on equity (ROE) is -69.65% and return on invested capital (ROIC) is -41.81%.
| Return on Equity (ROE) | -69.65% |
| Return on Assets (ROA) | -38.07% |
| Return on Invested Capital (ROIC) | -41.81% |
| Return on Capital Employed (ROCE) | -69.97% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$860,532 |
| Employee Count | 299 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.11% in the last 52 weeks. The beta is 0.60, so RCKT's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | -78.11% |
| 50-Day Moving Average | 3.40 |
| 200-Day Moving Average | 5.62 |
| Relative Strength Index (RSI) | 56.34 |
| Average Volume (20 Days) | 3,137,407 |
Short Selling Information
The latest short interest is 12.40 million, so 11.49% of the outstanding shares have been sold short.
| Short Interest | 12.40M |
| Short Previous Month | 13.70M |
| Short % of Shares Out | 11.49% |
| Short % of Float | 15.84% |
| Short Ratio (days to cover) | 3.94 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -264.18M |
| Pretax Income | -257.30M |
| Net Income | -257.30M |
| EBITDA | -253.87M |
| EBIT | -264.18M |
| Earnings Per Share (EPS) | -$2.49 |
Full Income Statement Balance Sheet
The company has $271.49 million in cash and $25.20 million in debt, giving a net cash position of $246.29 million or $2.28 per share.
| Cash & Cash Equivalents | 271.49M |
| Total Debt | 25.20M |
| Net Cash | 246.29M |
| Net Cash Per Share | $2.28 |
| Equity (Book Value) | 354.21M |
| Book Value Per Share | 3.28 |
| Working Capital | 233.76M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$203.80 million and capital expenditures -$2.31 million, giving a free cash flow of -$206.11 million.
| Operating Cash Flow | -203.80M |
| Capital Expenditures | -2.31M |
| Free Cash Flow | -206.11M |
| FCF Per Share | -$1.91 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RCKT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.53% |
| Shareholder Yield | -13.53% |
| Earnings Yield | -61.94% |
| FCF Yield | -49.61% |
Dividend Details Analyst Forecast
The average price target for RCKT is $12.88, which is 234.55% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.88 |
| Price Target Difference | 234.55% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -24.42% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |